SEARCH

SEARCH BY CITATION

References

  • 1
    Guzmán B. The Hispanic population: Census 2000 brief. Washington, DC: US Department of Commerce, Economics and Statistics Administration, US Census Bureau; 2001.
  • 2
    US Census Bureau. Current population survey, annual social and economic supplement, 2004. Available at: http://www.census.gov/population/socdemo/hispanic/ASEC 2004/2004CPS_tab1.1a.html. Accessed on June 18, 2007.
  • 3
    Ferdinand KC. Hypertension in minority populations. J Clin Hypertens (Greenwich). 2006;8:365368.
  • 4
    American Heart Association. Heart Disease and Stroke Statistics—2007 Update At-a-Glance. Dallas, TX: American Heart Association; 2007.
  • 5
    Qureshi AI, Suri MFK, Kirmani JF, et al. Prevalence and trends of prehypertension and hypertension in United States: National Health and Nutrition Examination Surveys 1976 to 2000. Med Sci Monit. 2005;11:CR403CR409.
  • 6
    Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003;290:199206.
  • 7
    Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension. 2007;49:6975.
  • 8
    Centers for Disease Control and Prevention. Hypertension-related mortality among Hispanic subpopulations: United States, 1995–2002. MMWR Morb Mortal Wkly Rep. 2006;55:177180.
  • 9
    The Office of Minority Health. Diabetes and Hispanic Americans. http://;www.omhrc.gov/templates/content.aspx?ID=3324 Accessed on May 24, 2007.
  • 10
    Narayan KM, Boyle JP, Thompson TJ, et al. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003;290:18841890.
  • 11
    Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension. 1992;19:403418.
  • 12
    Grossman E, Messerli FH. Diabetic and hypertensive heart disease. Ann Intern Med. 1996;125:304310.
  • 13
    Benabe JE, Rios EV. Kidney disease in the Hispanic population: facing the growing challenge. J Natl Med Assoc. 2004;96:789798.
  • 14
    Sorof JM, Lai D, Turner J, et al. Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics. 2004;113:475482.
  • 15
    Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356359.
  • 16
    Wong ND, Lopez V, Tang S, et al. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol. 2006;98:204208.
  • 17
    Giles T, Aranda JM Jr, Suh DC, et al. Ethnic/racial variations in blood pressure awareness, treatment, and control. J Clin Hypertens (Greenwich). 2007;9:345354.
  • 18
    Henderson SO, Bretsky P, DeQuattro V, et al. Treatment of hypertension in African Americans and Latinos: the effect of JNC VI on urban prescribing practices. J Clin Hypertens (Greenwich). 2003;5:107112.
  • 19
    Hicks LS, Fairchild DG, Horng MS, et al. Determinants of JNC VI guideline adherence, intensity of drug therapy, and blood pressure control by race and ethnicity. Hypertension. 2004;44:429434.
  • 20
    Aranda JM Jr, Vazquez R. Awareness of hypertension and diabetes in the Hispanic community. Clin Cornerstone. 2004;6:715.
  • 21
    He J, Muntner P, Chen J, et al. Factors associated with hypertension control in the general population of the United States. Arch Intern Med. 2002;162:10511058.
  • 22
    Kramer H, Han C, Post W, et al. Racial/ethnic differences in hypertension and hypertension treatment and control in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Hypertens. 2004;17:963970.
  • 23
    Soto-Greene ML, Salas-Lopez D, Sanchez J, et al. Antecedents to effective treatment of hypertension in Hispanic populations. Clin Cornerstone. 2004;6:3036.
  • 24
    Perez-Stable EJ, Salazar R. Issues in achieving compliance with antihypertensive treatment in the Latino population. Clin Cornerstone. 2004;6:4961.
  • 25
    Lai LL. Community pharmacy-based hypertension disease management program in a Latino/Hispanic-American population. Consult Pharm. 2007;22:411416.
  • 26
    National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:12061252.
  • 27
    Weir MR, Chrysant SG, McCarron DA, et al. Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. Hypertension. 1998;31:10881096.
  • 28
    Ofili EO, Ferdinand KC, Saunders E, et al; INCLUSIVE Investigators. Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. J Natl Med Assoc. 2006;98:618626.
  • 29
    Ridker PM, Danielson E, Rifai N, et al; Val-MARC Investigators. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension. 2006;48:7379.
  • 30
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:29812997.
  • 31
    Cooper-DeHoff RM, Aranda JM Jr, Gaxiola E, et al; INVEST Investigators. Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients: findings from the International Verapamil SR/Trandolapril Study (INVEST). Am Heart J. 2006;151:10721079.
  • 32
    Yusuf S, Gerstein H, Hoogwerf B, et al; HOPE Study Investigators. Ramipril and the development of diabetes. JAMA. 2001;286:18821885.
  • 33
    Lindholm LH, Ibsen H, Borch-Jahnsen K, et al; LIFE study group. Risk of new-onset diabetes in the Losartan Intervention for Endpoint reduction in hypertension study. J Hypertens. 2002;20:18791886.
  • 34
    Niklason A, Hedner T, Niskanen L, et al; Captopril Prevention Project Study Group. Development of diabetes is retarded by ACE inhibition in hypertensive patients—a subanalysis of the Captopril Prevention Project (CAPPP). J Hypertens. 2004;22:645652.
  • 35
    Kjeldsen SE, Julius S, Mancia G, et al; VALUE Trial Investigators. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens. 2006;24:14051412.
  • 36
    Jandeleit-Dahm KA, Tikellis C, Reid CM, et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens. 2005;23:463473.
  • 37
    Brenner BM, Cooper ME, De Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861869.
  • 38
    Eijkelkamp WB, Zhang Z, Remuzzi G, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol. 2007;18:15401546.